Form 4: Phathom Pharmaceuticals Director Exercises Stock Options
SEC Form 4 Filing
Asit Parikh, a director at Phathom Pharmaceuticals, exercised stock options on September 10, 2024, acquiring 7,500 shares of common stock.
Summary
- On September 10, 2024, Asit Parikh, a director of Phathom Pharmaceuticals, exercised stock options to acquire 7,500 shares of common stock at a price of $11.72 per share.
- Following the transaction, Parikh directly owns 93,000 shares of Phathom Pharmaceuticals.
- The stock options were exercisable starting May 25, 2024, and expire on May 24, 2033.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director exercising stock options. While insider activity can be interpreted as a sign of confidence, it's not definitively positive or negative without further context.
Positives
- The exercise of stock options by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/25/2024 | Date the stock options became exercisable |
| 09/10/2024 | Date of the transaction (exercise of stock options) |
| 03/21/2025 | Date of signature for the Form 4 filing |
| 05/24/2033 | Expiration date of the stock options |
Keywords
Phathom Pharmaceuticals, Director, Stock Options, Form 4, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.